These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 8632574

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Witjes WP, Schulman CC, Debruyne FM.
    Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
    Soloway MS, Hachiya T, Civantos F, Murphy WM, Gomez CC, Ruiz HE.
    Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
    [Abstract] [Full Text] [Related]

  • 9. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
    Akaza H, Homma Y, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Ohashi Y, Aso Y.
    Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
    [Abstract] [Full Text] [Related]

  • 10. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
    Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE.
    Am J Surg Pathol; 1994 Oct; 18(10):979-91. PubMed ID: 7522415
    [Abstract] [Full Text] [Related]

  • 11. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 12. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.
    Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Aoki M, Takai Y.
    World J Surg Oncol; 2014 Apr 30; 12():134. PubMed ID: 24885947
    [Abstract] [Full Text] [Related]

  • 13. Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
    Voges GE, Mottrie AM, Fichtner J, Mappes C, Störkel S, Stöckle M, Hohenfellner R.
    Eur Urol; 1995 Apr 30; 28(3):209-14. PubMed ID: 8536774
    [Abstract] [Full Text] [Related]

  • 14. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A.
    JAMA; 1998 Sep 16; 280(11):969-74. PubMed ID: 9749478
    [Abstract] [Full Text] [Related]

  • 15. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F, Kaplan M, Soloway MS.
    Br J Urol; 1996 Mar 16; 77(3):423-8. PubMed ID: 8814850
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.
    Int J Clin Oncol; 2015 Oct 16; 20(5):1018-25. PubMed ID: 25681879
    [Abstract] [Full Text] [Related]

  • 17. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
    Rabbani F, Goldenberg SL, Klotz LH.
    J Urol; 1998 Mar 16; 159(3):925-8. PubMed ID: 9474184
    [Abstract] [Full Text] [Related]

  • 18. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K, Sasaki H, Kido M, Takahashi H, Aoki M, Egawa S.
    BMC Cancer; 2016 Sep 01; 16(1):708. PubMed ID: 27586506
    [Abstract] [Full Text] [Related]

  • 19. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K, Satoh T, Matsumoto K, Fujita T, Irie A, Iwamura M, Yanagisawa N, Matsuda D, Muramoto M, Kadowaki K, Suyama K, Shoji K, Koh H, Kawakami T, Okayasu I, Egawa S, Baba S.
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul 01; 97(5):712-8. PubMed ID: 16898594
    [Abstract] [Full Text] [Related]

  • 20. Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
    Maru S, Uchino H, Osawa T, Chiba S, Mouri G, Sazawa A.
    PLoS One; 2018 Jul 01; 13(5):e0197252. PubMed ID: 29795595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.